Health Trials

H3 K27M

2

Review clinical trials related to H3 K27M. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.

Participants needed: 510
Trial details
Phase: Phase 3Biological sex: AllType: InterventionalSponsor: Jazz PharmaceuticalsUpdated: Apr 16, 2026Locations: 162
Eligibility criteria

Able to understand the study procedures and agree to participate in the study by... [+10]

Primary spinal tumor. [+23]

Read more
Status: Recruiting

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.

Participants needed: 20
Trial details
Phase: Phase 1, Phase 2Age: 1-21Biological sex: AllType: InterventionalSponsor: University of MiamiUpdated: Dec 8, 2025Locations: 1
Eligibility criteria

Documented histologic diagnosis of relapsed or refractory glioblastoma multiform... [+11]

Females who are pregnant or lactating [+2]

Read more